NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

NCT06963021 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Major Depressive Disorder

Interventions

DRUG: NBI-1065845
DRUG: Placebo

Sponsor

Neurocrine Biosciences